Agios Pharmaceuticals Inc (AGIO)
43.11
-0.50
(-1.15%)
USD |
NASDAQ |
Jun 28, 16:00
43.03
-0.08
(-0.19%)
After-Hours: 20:00
Agios Pharmaceuticals Research and Development Expense (TTM): 296.84M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 296.84M |
| December 31, 2023 | 295.53M |
| September 30, 2023 | 288.34M |
| June 30, 2023 | 271.46M |
| March 31, 2023 | 277.09M |
| December 31, 2022 | 279.91M |
| September 30, 2022 | 282.91M |
| June 30, 2022 | 281.94M |
| March 31, 2022 | 269.43M |
| December 31, 2021 | 256.97M |
| September 30, 2021 | 243.10M |
| June 30, 2021 | 231.04M |
| March 31, 2021 | 223.12M |
| December 31, 2020 | 220.81M |
| September 30, 2020 | 71.00M |
| June 30, 2020 | 120.73M |
| March 31, 2020 | 174.04M |
| December 31, 2019 | 214.26M |
| September 30, 2019 | 398.46M |
| June 30, 2019 | 379.34M |
| March 31, 2019 | 358.68M |
| December 31, 2018 | 341.32M |
| September 30, 2018 | 324.73M |
| Date | Value |
|---|---|
| June 30, 2018 | 315.09M |
| March 31, 2018 | 308.17M |
| December 31, 2017 | 292.68M |
| September 30, 2017 | 280.14M |
| June 30, 2017 | 267.87M |
| March 31, 2017 | 238.86M |
| December 31, 2016 | 220.16M |
| September 30, 2016 | 192.42M |
| June 30, 2016 | 167.80M |
| March 31, 2016 | 153.42M |
| December 31, 2015 | 141.83M |
| September 30, 2015 | 139.76M |
| June 30, 2015 | 129.25M |
| March 31, 2015 | 115.41M |
| December 31, 2014 | 100.37M |
| September 30, 2014 | 80.79M |
| June 30, 2014 | 70.06M |
| March 31, 2014 | 60.45M |
| December 31, 2013 | 54.50M |
| September 30, 2013 | 50.45M |
| June 30, 2013 | 45.44M |
| March 31, 2013 | 42.95M |
| December 31, 2012 | 41.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
71.00M
Minimum
Sep 2020
398.46M
Maximum
Sep 2019
247.21M
Average
269.43M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Arcutis Biotherapeutics Inc | 98.37M |
| Insmed Inc | 564.23M |
| Krystal Biotech Inc | 45.10M |
| Arvinas Inc | 368.80M |
| BridgeBio Pharma Inc | 503.82M |